# Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

Study · id `cardio:ct-nct03984760` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03984760](<https://clinicaltrials.gov/study/NCT03984760>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03984760

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

## Technical summary

Registry record NCT03984760. Randomized; no masking; primary purpose treatment. Start 2019-06-19 (actual); primary completion 2021-02-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 240 participants (enrolled count; ClinicalTrials.gov record NCT03984760, source copy `cardio:ctgov-nct03984760-2021-03-10`, retrieved 2026-10-26)
- Started: 2019-06-19 (actual) (ClinicalTrials.gov record NCT03984760, source copy `cardio:ctgov-nct03984760-2021-03-10`, retrieved 2026-10-26)
- Primary completion: 2021-02-20 (actual) (ClinicalTrials.gov record NCT03984760, source copy `cardio:ctgov-nct03984760-2021-03-10`, retrieved 2026-10-26)
- Completion: 2021-02-20 (actual) (ClinicalTrials.gov record NCT03984760, source copy `cardio:ctgov-nct03984760-2021-03-10`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03984760, source copy `cardio:ctgov-nct03984760-2021-03-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03984760-2021-03-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
- Condition: Hyperphosphatemia
- Condition: End Stage Renal Disease
- Condition: ESRD
- Intervention (Drug): Ferric Citrate
- Intervention (Drug): Sevelamer Carbonate
- Lead sponsor: Panion & BF Biotech Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Shandong Weigao Panion Pharmaceutical Co. Ltd.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Panion & BF Biotech Inc. (`cardio:org-panion-bf-biotech-inc`)

## Provenance

Content hash: b3cdcb66c3fcd84a7ec29ca02e4c80a28f8435001bb6c94fe95212136a595978
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
